JP2008516004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008516004A5 JP2008516004A5 JP2007543041A JP2007543041A JP2008516004A5 JP 2008516004 A5 JP2008516004 A5 JP 2008516004A5 JP 2007543041 A JP2007543041 A JP 2007543041A JP 2007543041 A JP2007543041 A JP 2007543041A JP 2008516004 A5 JP2008516004 A5 JP 2008516004A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- salt
- radioisotope
- granule
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61680504P | 2004-10-07 | 2004-10-07 | |
| US60/616,805 | 2004-10-07 | ||
| PCT/US2005/035921 WO2007050050A2 (en) | 2004-10-07 | 2005-10-06 | Thiazolyl mglur5 antagonists and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014184615A Division JP2015013885A (ja) | 2004-10-07 | 2014-09-10 | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008516004A JP2008516004A (ja) | 2008-05-15 |
| JP2008516004A5 true JP2008516004A5 (enExample) | 2014-10-30 |
| JP5635727B2 JP5635727B2 (ja) | 2014-12-03 |
Family
ID=37968242
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543041A Expired - Fee Related JP5635727B2 (ja) | 2004-10-07 | 2005-10-06 | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
| JP2014184615A Pending JP2015013885A (ja) | 2004-10-07 | 2014-09-10 | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014184615A Pending JP2015013885A (ja) | 2004-10-07 | 2014-09-10 | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7879882B2 (enExample) |
| EP (2) | EP1893608B1 (enExample) |
| JP (2) | JP5635727B2 (enExample) |
| CN (1) | CN101223166B (enExample) |
| AT (1) | ATE520692T1 (enExample) |
| AU (1) | AU2005336513B2 (enExample) |
| CA (1) | CA2583572C (enExample) |
| ES (1) | ES2369783T3 (enExample) |
| WO (1) | WO2007050050A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5635727B2 (ja) | 2004-10-07 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| TW201124391A (en) * | 2009-10-20 | 2011-07-16 | Lundbeck & Co As H | 2-substituted-ethynylthiazole derivatives and uses of same |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US8772300B2 (en) * | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
| KR101576343B1 (ko) * | 2011-04-26 | 2015-12-09 | 에프. 호프만-라 로슈 아게 | 피라졸리딘-3-온 유도체 |
| CA2829170C (en) * | 2011-04-26 | 2019-02-26 | F. Hoffmann-La Roche Ag | Ethynyl derivatives as positive allosteric modulators of the mglur5 |
| EP2953933A1 (en) | 2013-02-07 | 2015-12-16 | Merck Patent GmbH | Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4 |
| UA116023C2 (uk) * | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
| WO2015188368A1 (en) | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
| JP6603334B2 (ja) | 2015-06-03 | 2019-11-06 | エフ．ホフマン−ラ ロシュ アーゲー | エチニル誘導体 |
| RU2020105929A (ru) | 2017-08-04 | 2021-09-06 | Скайхоук Терапьютикс, Инк. | Способы и композиции для модулирования сплайсинга |
| JP7603592B2 (ja) | 2019-02-05 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| EP3920926A4 (en) | 2019-02-05 | 2022-10-19 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN119638696A (zh) | 2019-02-06 | 2025-03-18 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7365074B2 (en) | 1999-08-31 | 2008-04-29 | Merck & Co., Inc. | Pyridazine, pyrimidine and pyrazine ethyne compounds |
| US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
| JP4815083B2 (ja) * | 1999-08-31 | 2011-11-16 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環化合物およびそれの使用方法 |
| US7462619B2 (en) | 1999-08-31 | 2008-12-09 | Merck & Co., Inc. | Pyridazine, pyrimidine and pyrazine ethyne compounds |
| US6956049B1 (en) | 1999-08-31 | 2005-10-18 | Merck & Co., Inc. | Methods of modulating processes mediated by excitatory amino acid receptors |
| US6551270B1 (en) | 2000-08-30 | 2003-04-22 | Snowden Pencer, Inc. | Dual lumen access port |
| US6903005B1 (en) | 2000-08-30 | 2005-06-07 | Micron Technology, Inc. | Method for the formation of RuSixOy-containing barrier layers for high-k dielectrics |
| EP1556142A4 (en) * | 2002-10-24 | 2006-11-08 | Merck & Co Inc | ALKYN DERIVATIVES AS TRACERS FOR THE METABOTROPE GLUTAMATE RECEPTOR BINDING |
| JP5635727B2 (ja) * | 2004-10-07 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
-
2005
- 2005-10-06 JP JP2007543041A patent/JP5635727B2/ja not_active Expired - Fee Related
- 2005-10-06 EP EP05858618A patent/EP1893608B1/en not_active Expired - Lifetime
- 2005-10-06 CA CA2583572A patent/CA2583572C/en not_active Expired - Lifetime
- 2005-10-06 EP EP11167527.8A patent/EP2380889B1/en not_active Expired - Lifetime
- 2005-10-06 WO PCT/US2005/035921 patent/WO2007050050A2/en not_active Ceased
- 2005-10-06 US US11/664,902 patent/US7879882B2/en active Active
- 2005-10-06 AT AT05858618T patent/ATE520692T1/de not_active IP Right Cessation
- 2005-10-06 AU AU2005336513A patent/AU2005336513B2/en not_active Ceased
- 2005-10-06 ES ES05858618T patent/ES2369783T3/es not_active Expired - Lifetime
- 2005-10-06 CN CN2005800415189A patent/CN101223166B/zh not_active Expired - Fee Related
-
2011
- 2011-01-28 US US13/016,304 patent/US8242143B2/en not_active Expired - Lifetime
-
2012
- 2012-07-26 US US13/558,537 patent/US8609852B2/en not_active Expired - Lifetime
-
2014
- 2014-09-10 JP JP2014184615A patent/JP2015013885A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516004A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| JP2006526031A5 (enExample) | ||
| JP2021001196A5 (enExample) | ||
| IL259851A (en) | Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders | |
| JP2009502743A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2018534348A5 (enExample) | ||
| JP2013519632A5 (enExample) | ||
| JP2005518413A5 (enExample) | ||
| JP2007302683A5 (enExample) | ||
| JP2016006096A5 (enExample) | ||
| JP2006526590A5 (enExample) | ||
| JP2007514005A5 (enExample) | ||
| JP2011527299A5 (enExample) | ||
| JP2008519768A5 (enExample) | ||
| JP2008513510A5 (enExample) | ||
| BR0111868A (pt) | Composições farmacêuticas | |
| JP2004532828A5 (enExample) | ||
| JP2005509503A5 (enExample) | ||
| JP2009517411A5 (enExample) | ||
| JP2010500284A5 (enExample) | ||
| CA2489140A1 (en) | Dosage form containing pantoprazole as active ingredient |